Endocrinology

Survodutide: Is 9.8% weight loss enough for its GI cost?

SYNCHRONIZE-2 in NEJM: survodutide 6.0 mg cut weight 9.8% versus 3.9% on placebo over 76 weeks in type 2 diabetes, but about 1 in 4 stopped treatment.

Rotavirus vaccine and T1D: Is an 11% rise cause for alarm?

Type 1 diabetes incidence in Norwegian children rose 11% after rotavirus vaccination began, but similar rises followed unrelated vaccine changes.

Low-carb diets in kids with type 1 diabetes: safe, but not standard?

In 45,569 children, very low carbohydrate diets were not linked to poorer growth, severe hypoglycaemia or ketoacidosis, though the evidence remains observational.

Type 1 diabetes screening: Why one protocol worked across 8 nations

EDENT1FI tested 140,568 young people and found early-stage type 1 diabetes in about 1 in 45 with a relative and 1 in 350 without, across 8 countries.

CBL-514: Is visceral fat reduction the real story?

CBL-514 reduced visceral fat volume by 10.45% versus a 11.76% rise on placebo in a 40-person MRI subgroup, but the weight regain claim rests on rat data.

Amylin plus tirzepatide: Is 23% weight loss the new benchmark?

Eloralintide combined with tirzepatide cut body weight by up to 23.3% at 48 weeks in adults with obesity and type 2 diabetes, phase 2b data show.

Bariatric surgery: The hidden hernia risk you're missing

Up to 20% of bariatric surgery candidates present with pre-existing ventral hernias, a significant comorbidity often overlooked in surgical planning.

Marathon running with type 1 diabetes: Is it finally safe?

Adults with type 1 diabetes can safely complete marathons by leveraging continuous glucose monitoring (CGM) and traditional glucometers for real-time glucose management.

Insulin dosing apps: Are we overcomplicating type 2 diabetes care?

An insulin dosing app has received FDA clearance for adults with type 2 diabetes, aiming to streamline basal insulin titration and improve glycemic control.